Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 315

1.

Methodological quality of economic evaluations of new pharmaceuticals in The Netherlands.

Hoomans T, Severens JL, van der Roer N, Delwel GO.

Pharmacoeconomics. 2012 Mar;30(3):219-27. doi: 10.2165/11539850-000000000-00000.

PMID:
22074610
2.

[Cost-effectiveness of new drugs impacts reimbursement decision making but room for improvement].

Hoomans T, van der Roer N, Severens JL, Delwel GO.

Ned Tijdschr Geneeskd. 2010;154:A958. Dutch.

PMID:
20699045
3.

Unravelling drug reimbursement outcomes: a comparative study of the role of pharmacoeconomic evidence in Dutch and Swedish reimbursement decision making.

Franken M, Nilsson F, Sandmann F, de Boer A, Koopmanschap M.

Pharmacoeconomics. 2013 Sep;31(9):781-97. doi: 10.1007/s40273-013-0074-1.

PMID:
23839699
4.

[Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria].

F├╝hrlinger S.

Wien Med Wochenschr. 2006 Dec;156(23-24):612-8. German.

PMID:
17211765
5.

[Pharmaco-economic evaluations of new drugs: potential key to a more efficient allocation of the health care budget].

Delwel GO, Sprenger MJ.

Ned Tijdschr Geneeskd. 2002 Jun 8;146(23):1068-71. Dutch.

PMID:
12085554
6.

The evaluation and use of economic evidence to inform cancer drug reimbursement decisions in Canada.

Yong JH, Beca J, Hoch JS.

Pharmacoeconomics. 2013 Mar;31(3):229-36. doi: 10.1007/s40273-012-0022-5.

PMID:
23322588
7.

Using pharmacoeconomic analysis to make drug insurance coverage decisions.

Anis AH, Rahman T, Schechter MT.

Pharmacoeconomics. 1998 Jan;13(1 Pt 2):119-26.

PMID:
10176146
8.

Penny and pound wise: pharmacoeconomics from a governmental perspective.

van Oostenbruggen MF, Jansen RB, Mur K, Kooijman H.

Pharmacoeconomics. 2005;23(3):219-26. Review.

PMID:
15836004
9.

Belgian methodological guidelines for pharmacoeconomic evaluations: toward standardization of drug reimbursement requests.

Cleemput I, van Wilder P, Huybrechts M, Vrijens F.

Value Health. 2009 Jun;12(4):441-9. doi: 10.1111/j.1524-4733.2008.00469.x. Epub 2008 Nov 11.

10.

Using economic evaluations to make formulary coverage decisions. So much for guidelines.

Anis AH, Gagnon Y.

Pharmacoeconomics. 2000 Jul;18(1):55-62.

PMID:
11010604
11.

Do reassessments reduce the uncertainty of decision making? Reviewing reimbursement reports and economic evaluations of three expensive drugs over time.

Sandmann FG, Franken MG, Steenhoek A, Koopmanschap MA.

Health Policy. 2013 Oct;112(3):285-96. doi: 10.1016/j.healthpol.2013.03.006. Epub 2013 Apr 28.

PMID:
23628483
12.

Review of regulatory recommendations for orphan drug submissions in the Netherlands and Scotland: focus on the underlying pharmacoeconomic evaluations.

Vegter S, Rozenbaum MH, Postema R, Tolley K, Postma MJ.

Clin Ther. 2010 Aug;32(9):1651-61. doi: 10.1016/j.clinthera.2010.08.006.

PMID:
20974323
13.
14.

"Cost-effectiveness" estimates result in flawed decision-making in listing drugs for reimbursement.

West R, Borden EK, Collet JP, Rawson NS, Tonks RS.

Can J Public Health. 2002 Nov-Dec;93(6):421-5.

PMID:
12448863
15.

Economic evaluation of drugs and its potential uses in policy making.

Johannesson M.

Pharmacoeconomics. 1995 Sep;8(3):190-8. Review.

PMID:
10172485
17.

Health economic evaluations in reimbursement decision making in the Netherlands: time to take it seriously?

Franken M, Koopmanschap M, Steenhoek A.

Z Evid Fortbild Qual Gesundhwes. 2014;108(7):383-9. doi: 10.1016/j.zefq.2014.06.016. Epub 2014 Aug 12.

PMID:
25444296
18.

[Agreement between guidelines for pharmaco-economic research and never-before-published health-economics evaluations].

Postma MJ, Kwik JJ, Rutten WJ, de Jong-van den Berg LT, Brouwers JR.

Ned Tijdschr Geneeskd. 2002 Jun 8;146(23):1082-7. Dutch.

PMID:
12085558
19.

[Pharmacoeconomic studies - usability for reimbursement decisions].

Dietrich ES, Nakashima T, Ahrens S.

Dtsch Med Wochenschr. 2010 Feb;135(8):333-8. doi: 10.1055/s-0029-1244855. Epub 2010 Feb 17. Review. German.

PMID:
20165996
20.

[Current state and challenges of pharmacoeconomic evaluation in Korea].

Choi SE.

J Prev Med Public Health. 2008 Mar;41(2):74-9. Korean.

PMID:
18385546

Supplemental Content

Support Center